3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2.

Sets of 3-alkenyl-2-oxindoles (6,10,13) were synthesized in a facile synthetic pathway through acid dehydration (EtOH/HCl) of the corresponding 3-hydroxy-2-oxoindolines (5,9,12). Single crystal (10a,c) and powder (12a,26f) X-ray studies supported the structures. Compounds 6c and 10b are the most effective agents synthesized (about 3.4, 3.3 folds, respectively) against PaCa2 (pancreatic) cancer cell line relative to the standard reference used (Sunitinib). Additionally, compound 10b reveals antiproliferative properties against MCF7 (breast) cancer cell with IC50 close to that of Sunitinib. CAM testing reveals that compounds 6 and 10 demonstrated qualitative and quantitative decreases in blood vessel count and diameter with efficacy comparable to that of Sunitinib, supporting their anti-angiogenic properties. Kinase inhibitory properties support their multi-targeted inhibitory activities against VEGFR-2 and c-kit in similar behavior to that of Sunitinib. Cell cycle analysis studies utilizing MCF7 exhibit that compound 6b arrests the cell cycle at G1/S phase while, 10b reveals accumulation of the tested cell at S phase. Compounds 6a and 10b reveal potent antiviral properties against SARS-CoV-2 with high selectivity index relative to the standards (hydroxychloroquine, chloroquine). Safe profile of the potent synthesized agents, against normal cells (VERO-E6, RPE1), support the possible development of better hits based on the attained observations.

Introduction

Many 3-alkenyl-2-oxindole analogs were naturally isolated revealing diverse biological properties [1]. Sunitinib (Sutent) which is a 3-alkenyl-2-oxindole derivative is an orally multi-target tyrosine kinase inhibitor approved by FDA (Food and Drug Administration on Jan. 26, 2006 and Nov. 16, 2017) for the treatment of gastrointestinal and advanced renal cancers. It has been also approved for the treatment of pancreatic cancer (May 20, 2011) [2], [3]. Semaxanib, another member of this family, is a VEGFR (vascular endothelial growth factor receptor) inhibitor discontinued in 2002 during phase III clinical trials for colorectal cancer [4] (Fig. 1 ). Cancer is one of the most serious human health challenges universally. It is the second life deadly disease after cardiovascular disorders. WHO (World Health Organization) reported 1/6 deaths globally is due to cancer in 2018 (9.6 million deaths) [5], [6]. Although many targeted drugs are developed and clinically approved, the associated side effects and limited efficacies diminished their applications and demanded the need for novel chemical entities with safer cures and higher potencies [7].

Fig. 1

Biologically active 3-alkenyl-2-oxindoles, multi-targeted anticancer agents and Treanda (Bendamustine).

Many of the investigated anticancer agents/drugs obey “one-molecule – one target – one disease” phenomenon. This allows the emerging of an agent selectively targeting a single biological entity to avoid the risk of off-target side effects. However, this hypothesis seems inadequate for multi-genic diseases (such as cancer, Alzheimer's or Parkinson's disease). This is why multi-targeted inhibitors were developed which can exhibit therapeutic potencies towards various mechanisms [8], [9]. It has been reported that cancer initiation and progression depend on several receptors or singling pathways. This is why multi-targeted agents can provide several advantages over mono-targeted therapies. Several multi-target inhibitors (e.g. Sunitinib, Sorafenib, Altiratinib, Linifanib, and Regorafenib) were developed/approved, or investigated in clinical trials [10] (Fig. 1).

In our pursuit to develop novel antitumor agents [11], [12], [13], the present study describes the synthesis of 3-alkenyl-2-oxindoles conjugated with sulfonamide function. This fragment is an important component in many clinically approved antitumor drugs {e.g. Belinostat (Beleodaq) [14], [15], Dabrafenib (Tafinlar) [16], [17], Pazopanib (Votrient) [18], [19], Vemurafenib (Zelboraf) [20], [21] and Venetoclax (Venclexta) [22], [23]}.

Benzimidazolyl heterocycle is also considered for conjugation with the targeted compounds due to the diverse biological properties exhibited by its derivatives such as antitumor [24], [25], [26], [27], [28], [29], [30], [31], anti-inflammatory [32], antitubercular [33], [34], [35], anti-HIV (human immunodeficiency virus) [36], [37], [38], α-glucosidase inhibition [39], [40], [41], cholinesterase inhibitor useful to combat the neuromuscular disorders [42], pancreatic lipase inhibitor useful for fat absorption control [43], α-amylase inhibitor useful for diabetes, obesity, and oral diseases [44] and Rho-kinase inhibitor useful for treatment of glaucoma [45]. Treanda (Bendamustine hydrochloride) is a benzimidazolyl derivative approved by FDA (2008) for chronic lymphocytic leukemia [46], [47].

Antiproliferative properties of the targeted agents are considered against pancreatic (PaCa), colon (HCT116), and breast (MCF7) carcinoma cell lines. Adoption of the mentioned cell lines for testing is due to the high correlation of the synthesized agents with Sunitinib that show efficacy/clinical application against them. Additionally, pancreatic cancer is the twelfth most common cancer globally with 460,000 new cases in 2018 [48]. It usually develops from exocrine (more common) or neuroendocrine (less common with better prognosis) cells [49]. Colorectal cancer is a malignant tumor arising from genetic and epigenetic changes in colorectal epithelial cells [50]. Heredity, colon polyps, and long-standing ulcerative colitis are major factors that cause colon cancer [51]. Breast cancer is the second cause of female cancer (2.09 million cases) with death incidence 627,000 globally in 2018 according to WHO statistics [5].

The chick chorioallantoic membrane (CAM) assay model can be employed as an in vivo xenograft model for cancer cells. The cells form tumor xenografts by seeding onto the chorioallantoic membrane as a result, invasion occurs into a highly vascularized membrane. The CAM model can also be used to study angiogenesis due to the high vascularization of its membrane. The chorioallantoic membrane is composed mostly of type IV collagen, which resembles the human epithelium basement membrane [52], [53], [54], [55], [56], [57].

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) seems the most major health care disaster declared by WHO (World Health Organization) as a pandemic COVID-19 [58]. The story began in December 2019 (Wuhan, China) due to novel pneumonia by an unknown pathogen [59]. COVID-19 is a viral disease that belongs to the family Coronaviridae and genus Betacoronavirus [60]. By May 2021 about 162.2 million patients with 3.364 million deaths were reported worldwide [61]. Lack of available antiviral drugs/vaccines enforced the pharmaceutical authorities/companies to test any agent/drug with antiviral background (drug repurposing). Few agents were considered due to urgent needs (Fig. 2 ) to control global pandemic but most of them are with low potency and adverse effects [62]. This seems the top today's priority for the political and health authorities to save thousand(s)/million(s) of human life and economic collapse. Recently, few N-substituted isatins were reported as SARS-CoV-2 3CLpro inhibitors [63]. Due to this, the 3-alkenyl-2-oxindoles synthesized in the present study are screened for their antiviral properties against SARS-CoV-2. The recent reports describing the possibility for treating SARS-CoV-2 patients with anticancer drugs [64], [65] in addition to the successful clinical trial for treating colorectal

Fig. 2

Repurposing drugs for COVID-19.

carcinoma patients with antiviral drugs solely or in combination with anticancer drugs [66], also prompted the current study targeting developing novel hits of dual functions (antiviral and antitumor) with much attention to their safety profile towards normal cells.

Results and discussion

Chemistry

Reaction of 4-acetylphenyl alkanesulfonates 3a,b with isatins 4a,b in absolute ethanol containing quantitative amount of diethylamine at room temperature afforded the corresponding 4-[2-(3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl alkanesulfonates 5a-d in good yields (Scheme 1 ). Compounds 5a-d were isolated from the conducted reactions in adequate purity so, used directly in the next step without any further purification. IR spectrum of 5a (example of the agents prepared) reveals the ketonic and indolyl carbonyl bands at ν = 1701, 1675 cm−1 beside the hydroxyl, and indolyl NH as a broad–band at ν = 3291 cm−1. The methylene protons are diastereotopic shown as two doublet signals at δ H = 3.61, 4.09 (J = 17.5 Hz). The 13C NMR spectrum of 5a exhibits the indolyl C-3 and C-

Scheme 1

Synthetic route towards 5 and 6.

2 at δ C = 72.9, 178.2 respectively beside, the methylene and ketonic carbonyl at δ C = 45.7, 195.4, respectively.

Acidic dehydration (EtOH/HCl) of 5 afforded directly (E)-4-[2-(2-oxoindolin-3-ylidene)acetyl]phenyl alkanesulfonates 6 in excellent yields. 1H NMR spectrum of 6a shows the olefinic proton as a sharp singlet at δ H = 7.74. The indolyl and ketonic carbonyls are shown at δ C = 168.1, 190.0, respectively.

Similarly, N-[4-(2-(3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl)-N-(alkylsulfonyl)alkanesulfonamides 9a-d were obtained through the reaction of N-(4-acetylphenyl)-N-(alkylsulfonyl)alkanesulfonamide 8a,b with the corresponding isatins 4a,b. Meanwhile, reaction of N-(4-acetylphenyl)propane-1-sulfonamide (8c) with isatins 4a-c afforded the corresponding N-{4-[2-(3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(propylsulfonyl)propane-1-sulfonamide 9e-g. This is presumably formed due to propylsulfonate elimination from 8c, under the effect of the reaction basic catalysis used followed by a simultaneous attack to another molecule giving eventually the isolated products 9e-g. Acidic dehydration of 9 afforded the corresponding 10 in good yields (Scheme 2 ). 1H NMR of 10a-c reveal the olefinic proton as a singlet signal at δ H = 7.74–7.80. Single crystal X-ray studies of compounds 10a,c support the E-configuration (Fig. 3 ).

Scheme 2

Synthetic route towards 9 and 10.

Fig. 3

ORTEP view of compounds (A) 10a and (B) 10c showing the atom-numbering scheme. H atoms are shown as small spheres of arbitrary radii.

3-Hydroxy-3-[2-(1-alkyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]indolin-2-ones 12a-h were also obtained through base-catalyzed reaction of 1-alkyl-2-acetylbenzimidazoles 11a,b with isatins 4a-e which are formed in sufficient purity and used directly in the next step. Powder X-ray studies of compounds 12a,f add conclusive support for the structure (Fig. 4 ). 3-[2-(1-Alkyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-ones 13a–f could also be synthesized from the corresponding 12a-f through acidic dehydration. Acidic dehydration of 12 g,h under the same reaction conditions afforded 13a as a sole product. This is probably formed via cyclic-amino methylene elimination under the effect of the applied acidic reaction conditions (Scheme 3 ). 1H NMR spectra of 13a-f reveal the olefinic proton as a sharp singlet at δ H = 8.66–8.85. The downfield shift shown by these analogs relative to 6a-c and 10a-c can be attributed to the anisotropic effect of benzimidazolyl heterocycle (the spectral illustrations are presented in supplementary Figs. S1–S108).

Fig. 4

ORTEP view of compounds (A) 12a and (B) 12f showing the atom-numbering scheme. H atoms are shown as small spheres of arbitrary radii.

Scheme 3

Synthetic route towards 12 and 13.

X-ray studies

Single crystals suitable for Synchrotron single-crystal X-ray diffraction experiments were obtained for the compounds 10a and 10c. Compounds 10a and 10c crystallized in the monoclinic P21/c and triclinic P-1 space groups, respectively. ORTEP views of the compounds are shown in Fig. 3. In both structures, the 4-[2-(2-oxoindolin-3-ylidene)acetyl]phenyl system seems almost planar, forming a dihedral angle of 82.23° and 80.28° with the sulfonamide group of 10a and 10c, respectively. In 10a the torsion angle defined by C29-C30-C31-C32 is nearly planar (179.19°). Whereas, in the other independent molecule the same angle defined by C9-C10-C11-C16 is 150.23° resulting in a loss of planarity. In both compounds, the intermolecular hydrogen bond between the N(1, 3)H and the carbonyl group of the heterocycle with a bond length of 2.02 Å and 1.972 Å, respectively, stabilize the crystal structures (Supplementary Tables S1–S4, S8; Figs. S109, S110).

On the other hand, the indexing of the investigated X-ray powder diffraction data of compounds 12a and 12f resulted in the triclinic P-1 and monoclinic P21 /n space group, respectively with one molecule per asymmetric unit in each (Fig. 4). The torsion angles defined by C14-C13-C12-C9 show different values. It is nearly planar (176.5°) in compound 12a and out of plane in compound 12f (72.79°). As a consequence, the benzimidazolyl and indolyl heterocycles form a dihedral angle of 79.63° and 49.02° in the 12a and 12f, respectively. Moreover, this fact leads to a different intramolecular bond between the benzimidazolyl and indolyl heterocycles as in compound 12a is ruled by the N7-O15 bond distance of 2.69 Å. That is lost in the 12f and replaced by a slightly shorter N11-O1 bond distance of 2.52 Å. In the 12f there is a strong intermolecular H-bond between the N(7)–H and the carbonyl group of the heterocycle with a bond length of 1.786 Å (Supplementary Tables S5–S7, S9; Figs. S111, S112).

Biological studies

Antiproliferative properties

Standard MTT technique was considered for determining the antiproliferative properties of the synthesized compounds utilizing Sunitinib as a standard reference against pancreatic (PaCa-2), breast (MCF7), and colon (HCT116) cancer cell lines [67]. Table 1 reveals the cytotoxic properties of the targeted 3-alkenyl-2-oxindoles in IC50 (μM, concentrations exhibiting 50% cell growth inhibition relative to the control experiment). It has been noticed that all the synthesized 3-alkenyl-2-oxindoles 6a–c and 10a–c show remarkable antiproliferative properties against pancreatic cancer (PaCa-2) cell line with potency higher than that of Sunitinib. Compounds 6c and 10b are the most effective agents synthesized (about 3.4, 3.3 folds, respectively) relative to Sunitinib. Compound 6b also reveals high potency against PaCa2, three time folds relative to Sunitinib. On the other hand compound 10b is the most potent agent synthesized against MCF7 (breast) cancer cell line exhibiting IC50 close to that of the standard reference used (IC50 = 4.15, 3.97 µM for 10b and Sunitinib, respectively). Compounds 6b and 6c also reveal similar behavior with efficacy close to that of Sunitinib (IC50 = 4.25, 4.28 µM for 6b and 6c, respectively). However, compound 6c is the only synthesized analog with cytotoxic properties against HCT116 (colon) cancer cell line close to the standard reference used (IC50 = 5.33 and 5.03 μM corresponding to 6c and Sunitinib, respectively).

Table 1

Antiproliferative properties of the tested compounds.

Entry	Compd.	IC50 (μM) ± SE
		PaCa-2	MCF7	HCT116
1	6a	8.30 ± 0.44	6.85 ± 0.37	16.38 ± 0.70
2	6b	5.60 ± 0.57	4.25 ± 0.23	12.77 ± 1.41
3	6c	4.99 ± 0.29	4.28 ± 0.51	5.33 ± 0.46
4	10a	6.91 ± 0.89	6.07 ± 0.83	20.96 ± 1.75
5	10b	5.08 ± 0.57	4.15 ± 0.78	13.83 ± 1.06
6	10c	6.18 ± 0.32	4.43 ± 0.47	>50.00 ± 0.84
7	Sunitinib	16.91 ± 0.95	3.97 ± 0.14	5.03 ± 0.30

Based on the biological observations few SAR (structure–activity relationships) can be assigned. Attachment of the ethyl group to the sulfonate/sulfonamide fragment is critical in developing biological properties comparable with the methyl group as revealed in pairs 6a/6b and 10a/10b. It has also been noticed that in case of PaCa2 (pancreatic) and HCT116 (colon) cancer cell lines, attachment of chlorine atom to the indolyl heterocycle enhances the observed antiproliferative properties of the sulfonate containing-compounds as shown in the pair 6b/6c. On the other hand, utilization of benzimidazolyl heterocycle instead of the substituted phenyl quenched the targeted biological properties (as revealed in compounds 6a–c and 10a–c relative to compounds 13a–f). This can be attributed to the high insolubility (with high melting point) of the synthesized compounds 13 in aqueous media.

The cytotoxic properties of the effective agents synthesized (6a–c and 10a–c) were also determined against non-cancer RPE1 (retinal pigment epithelium) cell line. The observed data support the safety profile of all the tested analogs against the utilized normal cell line (IC50 > 50 μM). Antiproliferative properties of all the tested agents are shown in Supplementary Figs. S113–S116.

CAM assay

CAMs treated with the proposed synthesized agents (the most promising antiproliferative agents synthesized) 6a–c and 10a–c, control (vehicles, DMSO, PBS “Phosphate-buffered saline”, and ethanol) and positive control (Sunitinib) showed a significant difference in blood vessel number and diameter, either quantitatively (n = 4) or qualitatively (Fig. 5 A). In detail, CAMs treated with vehicle only showed the highest blood vessel diameters (14 mm). CAMs treated with Sunitinib showed reduction in blood vessel diameters in comparison to control (5 mm). Compounds 6a–c significantly reduced the blood vessel diameters to 3.2, 5.1, and 5.13 mm, respectively, compared to control. Compounds 10a–c also reduced the blood vessel diameters to 3.5, 2.7, and 5 mm, respectively, compared to control (Fig. 5B, Table 2 ). In order to support these observations, H&E (haematoxylin and eosin) staining for CAMs was performed. In this regard, H&E staining confirmed the mentioned observations (revealing reductions in the number of blood vessels) for the CAMs treated with the positive control (Sunitinib) and the tested agents 6a–c, 10a–c.

Fig. 5

(A) Images and histology using H&E of the chick embryo chorioallantoic membrane (CAM) for vehicle control, positive control (Sunitinib) and test compounds. At day 8, eggs were opened carefully. Twenty μl of control vehicle or test compounds (final concentration of 660 μM) were left to dry on a 2.5 cm round glass slide on the surface of the CAM blood network. Eggs were covered and left in an incubator at 37 °C for 3 days. Later the membrane around the area of interest was fixed with 5% formalin, and paraffin embedded for further staining. Original images were done at 40x and 100x magnification “CM: chorionic membrane. ML: mesodermal layer. BV: blood vessel”. (B) Quantitative analysis of blood vessel diameter in mm after 3 days of treatment. Sunitinib (positive control) and test compounds all show significant reduction in BV diameters. All results are expressed as mean ± SD (n = 4) (***P < 0.001 in comparison to control).

Table 2

Blood vessel diameter of tested compound and Sunitinib.

Entry	Compd.	Mean diameter of blood vessels (mm ± SD “standard division”)
1	Control	14.00 ± 3.00
2	Sunitinib	5.00 ± 0.71
3	6a	3.20 ± 1.00
4	6b	5.10 ± 1.00
5	6c	5.13 ± 0.90
6	10a	3.50 ± 0.50
7	10b	2.70 ± 0.40
8	10c	5.00 ± 0.40

The CAM assay is one of the most utilized techniques for determination of anti-angiogenic effects [68]. This is attributed to the highly vascularized membrane and that the chorioallantoic membrane is mostly composed of type IV collagen, which resembles the human epithelium basement membrane [52], [53], [54], [55], [56], [57]. Our results show that the promising antiproliferative synthesized agents 6a–c and 10a–c possess anti-angiogenic properties as they can decrease the number and diameter of the blood vessels with potency comparable to that of Sunitinib, which is a well-known drug with anti-angiogenic properties [69], [70], [71]. In conclusion, the synthesized agents 6 and 10 can be considered as potential anti-tumor agents with anti-angiogenic properties.

Kinase inhibitory properties

Angiogenesis is the formation of novel blood vessels/branches from the existing ones [72]. The new blood vessels are useful for nutrient and oxygen transportation to the endothelial cells that may stimulate and proliferate forming new sprouts. Regulated angiogenesis is an important process for embryonic development, reproduction, and wound healing due to cell growth and tissue re-generation [73]. On the other hand, dysregulated angiogenesis is observed in many diseases including solid cancers. This is why targeting dysregulated angiogenesis seems an important therapeutical approach for competing diverse cancer types and sometimes has been considered preferable to other chemotherapies to avoid the adverse effects on normal/healthy cells [74]. It has been reported that vascular endothelial growth factor receptors are three main categories (VEGFR-1, VEGFR-2, and VEGFR-3) responsible for tumor angiogenesis [75], [76]. VEGFR-2 is the main receptor capable for anti-angiogenesis and controlling tumor proliferation [74].

Table 3 (Fig. 6 ) exhibits the VEFGR-2 inhibitory properties of the promising antiproliferative 3-alkenyl-2-oxindoles (6a–c, 10a–c) synthesized. From the exhibited data it has been noticed that, compound 6c is the most potent VEGFR-2 inhibitor with 1.3 folds relative to that of Sunitinib (standard reference used). This observation is comparable to that shown by CAM testing (blood vessel diameter = 5.1, 5.0 mm by compound 6c and Sunitinib, respectively). Compound 10c also reveals promising VEGFR-2 inhibitory properties (IC50 = 53.36 nM, i.e. 0.89 fold relative to Sunitinib). This observation is comparable to the antiproliferative properties revealed for MCF7 (breast) cancer cell line (IC50 = 4.43, 3.97 µM for compound 10c and Sunitinib, respectively; i.e. 0.9 fold potency) and CAM testing (blood vessel diameter = 5.0 mm by both compound 10c and Sunitinib). Additionally, the promising VEGFR-2 exhibited by compound 6a (IC50 = 54.03 nM) also supports the revealed antiproliferative properties against MCF7 (IC50 = 6.85 µM).

Table 3

Kinase inhibitory properties of the promising antiproliferative 3-alkenyl-2-oxindoles (6a–c, 10a–c) synthesized and Sunitinib.

Entry	Compd.	IC50 (nM ± SD)
		VEGFR-2	c-kit
1	6a	54.03 ± 5.4	119.8 ± 12.0
2	6b	98.95 ± 9.9	247.7 ± 24.8
3	6c	36.86 ± 3.7	72.35 ± 7.2
4	10a	102.2 ± 10.2	103.3 ± 10.3
5	10b	74.06 ± 7.4	184.9 ± 18.5
6	10c	53.36 ± 5.3	81.7 ± 8.2
7	Sunitinib	47.54 ± 4.8	84.9 ± 8.5

Fig. 6

Kinase inhibitory properties of the tested compounds and Sunitinib.

The c-Kit receptor is a member of class III tyrosine kinase receptor [77]. Overexpression of c-kit initiates cell proliferation and tumor creation [78]. Suppressing the c-kit was reported as an efficient therapeutic strategy for controlling many cancer types [79], [80], [81]. It has been reported that, the VEGFR-2 inhibitors may block/inhibit other tyrosine kinase receptors (e.g. c-Kit, PDGFRs, FGFRs, and Flt-3); due to the structural similarities so, can be recognized as multi-targeted tyrosine kinase inhibitors with accessibility against different cancer types [82]. Additionally, the chemical structural resemblance of the antiproliferative agents synthesized and Sunitinib also prompted screening the inhibitory properties of 6a–c and 10a–c towards c-kit. Considering that Sunitinib is approved as multi-targeted inhibitor against various kinases including VEGFR, PDGFR, FLT-3 and c-kit [83].

Table 3 (Fig. 6) reveals the inhibitory properties of the tested compounds against c-kit. It has been noticed that, compound 6c is a potent c-kit inhibitor with efficacy higher than that of the standard reference used, Sunitinib (IC50 = 72.35, 84.9 nM for 6c and Sunitinib, respectively). These observations can support the exhibited antiproliferative properties of 6c relative to Sunitinib as mentioned in the VEGFR-2 inhibitory observations. Compound 10c also reveals promising c-kit inhibitory properties close to that of Sunitinib (IC50 = 81.7, 84.9 nM for 10c and Sunitinib, respectively). These observations are comparable to their antiproliferative properties against MCF7 (breast) cancer cell line (IC50 = 4.43, 3.97 µM for compound 10c and Sunitinib, respectively). Generally, most of the revealed kinase (VEGFR-2 and c-kit) inhibitory properties observed by the tested compounds are consistent with their antitumor observations (Table 1). The slight differences shown are due to the environmental experimental conditions applied (standard protocols). It can also conclude that the synthesized agents are multi-targeted kinase receptor inhibitors (VEGFR-2 and c-kit).

Cell cycle study

Cell cycle analysis via quantitative DNA content is an important technique capable to identify the proliferation of culture cells and cell distribution in each phase of the cell cycle. Propidium iodide (PI) staining of DNA utilizing flow cytometry cell cycle analysis is an accessible technique for stoichiometric DNA cell content determination [84]. Arresting cell cycle during the transition from G1 phase to S phase seems an important mode for many antiproliferative active agents [85]. Compounds 6b and 10b (the most effective antiproliferation agents synthesized against breast cancer cell line) were subjected for induced cell cycle study of MCF7 utilizing the assigned IC50 value (Table 1). This identifies the cell cycle distribution and phase arresting during the antiproliferation inhibitory process of the bio-active agents. From the results obtained (Table 4 , Fig. 7, Fig. 8 ) it has been noticed that, compound 6b reveals decrease in the accumulated tested cells at G2/M relative to the control experiment (% G2/M = 2.67, 5.09 for compound 6b and control experiment, respectively; i.e. 47.5% decrease in cell population). However, slight accumulation of the tested cell at G1/S phase was observed relative to the control (%G0-G1 = 54.08, 53.79; %S = 43.25, 41.12 for compound 6b and control experiment, respectively). This identifies that compound 6b arrests the cell cycle at G1/S phase. On the other hand, compound 10b reveals accumulation of the tested cell at S phase higher than that of G0/G1 phase “also with about 13% increment in S phase

Table 4

Percentage cell distribution during induced cell cycle study for compounds 6b and 10b on MCF7 cells by PI-flow cytometry.

Entry	Compd.	DNA content (%)
		G0-G1	S	G2/M	Pre-G1
1	6a	54.08	43.25	2.67	34.71
2	10a	41.71	54.18	4.11	28.25
3	Control	53.79	41.12	5.09	1.49

Fig. 7

DNA content during induced cell cycle analysis study (MCF7) for the tested compounds and control experiment by PI-flow cytometry.

Fig. 8

Cell cycle analysis and apoptosis induced by the tested compounds and control experiment for MCF7.

than that of the control experiment” (%S = 54.18, 41.12 for compound 10b and control experiment, respectively). This supports the efficacy of compound 10b to arrest the tested cell at S phase.

Apoptosis induction [86] was also noticed by the bio-active agents synthesized 6b and 10b against MCF7 cell utilizing IC50 values discovered (Table 1). From the results obtained (Table 5 , Fig. 8) it has been noticed that compound 6b is a higher apoptosis performing agent than 10b. This is due to the increased late stage of apoptosis observed by 6b than 10b (% late stage = 22.91, 17.15 by compounds 6b and 10b, respectively). Compound 6b also reveals higher necrosis induction than 10b (% necrosis = 9.29, 7.07 by compounds 6b and 10b, respectively).

Table 5

Percentage apoptosis and necrosis for compounds 6b and 10b on MCF7 cells induced by IC50 values.

Entry	Compd.	Apoptosis (%)			Necrosis
		Total	Early	Late
1	6b	34.71	2.51	22.91	9.29
2	10b	28.25	4.03	17.15	7.07
3	Control	1.49	0.49	0.13	0.87

Antiviral properties

Antiviral properties of the synthesized 3-alkenyl-2-oxindoles (6a–c, 10a–c) against SARS-CoV-2 were determined by the standard technique [87], [88], [89] and compared with that of hydroxychloroquine, chloroquine and Favipiravir, which are used as standard references. Table 6 (Fig. 9 ) reveals the IC50 (concentration needed for 50% reduction of virus-induced cytopathic effect compared to control experiment) and the CC50 (concentration needed for 50% growth normal cell line “VERO-E6, needed for viral growth” inhibition relative to control experiment) for all the tested compounds. The SI (therapeutical/selectivity index, which is the ratio of CC50 relative to IC50) is an important parameter identifying the selectivity of the tested agent for the viral cell relative to the host normal cell. This is an important indicator explaining the safety profile of a tested agent.

Table 6

Antiviral properties of the tested compounds against SARS-CoV-2.

Entry	Compd.	IC50 (µM)a	CC50 (µM)b	SIc
1	6a	3.799	1377	362.5
2	6b	55.14	1313	23.8
3	6c	13.52	356.9	26.4
4	10a	219	1617	7.4
5	10b	3.417	566	165.6
6	10c	20.1	1517	75.5
7	Hydroxychloroquine	29.25	356.4	12.2
8	Chloroquine	19.78	377.7	19.1
9	Favipiravir	1382	2633	1.9

aCC50 = Cytotoxic concentration due to 50% growth compared to the control experiment.

b IC50 = Inhibitory concentration due to 50% growth compared to the control experiment.

c SI (Selectivity index/therapeutical index) =

Fig. 9

Dose-response curves for the tested compounds against SARS-CoV-2.

From the observed results, it can be concluded that many of the synthesized agents reveal antiviral properties with potency high than that of hydroxychloroquine (which reveals higher potency relative to the other standard references used, chloroquine and Favipiravir). Compounds 10b and 6a are superior among all the tested agents (IC50 = 3.417, 3.799 µM, for 10b and 6a, respectively). However, compound 6a seems a preferable agent than 10b for any higher biological testing due to the higher SI revealed (SI = 362.5, 165.6 for 6a and 10b, respectively). Compound 6c is also a promising agent with enhanced potency and selectivity index than the standard references used (IC50 = 13.52, 29.25, 19.78; SI = 26.4, 12.2, 19.1 for 6c, hydroxychloroquine and chloroquine, respectively). Compound 10c exhibits promising SI due to its high cytotoxicity value

(CC50) relative to the antiviral potency (IC50) value (IC50 = 20.1, CC50 = 1517 µM, SI = 75.5).

Molecular modeling

Molecular modeling is a computational technique intensively utilized in medicinal chemical studies. It is useful for identifying the parameters necessary for bio-properties via exploring the interaction taking place between the proposed bio-active agent and amino acids of the protein active site. This may support the assumed mode of action and assigning the agent’s functional group(s) necessary for the observed biological properties. Standard CDOCKER technique was considered in the current study (Discovery Studio 2.5 software; force field, CHARMm; partial charge method, MMFF94) utilizing PDB ID: 4AGD, 3G0E for VEGFR-2 and c-kit modeling respectively [90], [91], [92], [93]. Table 7 (Supplementary Figs. S117, S118) exhibits the molecular docking results for the promising antiproliferative agents synthesis (6a–c, 10a–c) and Sunitinib (reference standard used) in the PDB ID: 4AGD and 3G0E responsible for VEGFR-2 and c-kit inhibition, respectively.

Table 7

Molecular modeling results due to docking of compounds (6a–c, 10a–c) and Sunitinib in the PDB ID: 4AGD and 3G0E responsible for VEGFR-2 and c-kit inhibitors, respectively.

Entry	Compd.	PDB ID: 4AGD		PDB ID: 3G0E
		Docking scorea	Docking observations	Docking scorea	Docking observations
1	6a	−31.48	H-bond: indolyl CO - CYS919; π-σ interactions: indole - VAL848	−50.99	H-bond: indolyl CO - CYS673, indolyl NH - GLU671, sulfonyl SO-ASP677; π-σ interactions: indole–VAL603
2	6b	−40.07	H-bond: indolyl CO - CYS919, indolyl NH - GLU917	−50.69	H-bond: indolyl CO - CYS673, indolyl NH - GLU671; π-σ interactions: indole–VAL603
3	6c	−35.67	H-bond: indolyl CO - CYS919	−56.56	H-bond: indolyl CO - CYS673, indolyl NH - GLU671; π-σ interactions: indole–VAL603, phenyl-LEU595
4	10a	−34.67	H-bond: indolyl CO - CYS919, indolyl NH - GLU917	−57.88	H-bond: indolyl CO - CYS673, indolyl NH - GLU671, sulfonamide SO-ASP677; π-σ interactions: indole–VAL603
5	10b	−39.46	H-bond: indolyl CO - CYS919, indolyl NH - GLU917	−55.81	H-bond: indolyl CO - CYS673
6	10c	–33.29	H-bond: indolyl CO - CYS919, indolyl NH - GLU917	−58.33	H-bond: indolyl CO - CYS673, indolyl NH - GLU671, sulfonamide SO-ASP677
7	Sunitinib	−53.64	H-bond: indolyl CO - CYS919, indolyl NH - GLU917	−59.88	H-bond: indolyl CO - CYS673, indolyl NH - GLU671; π-σ interactions: indole–VAL603

Docking score in kcal mol−1.

VEGFR-2

Table 7 (Supplementary Fig. 117) reveals that, all the tested compounds aligned perfectly in the active site of the used protein in a similar manner/behavior to that of Sunitinib with different docking scores. All the tested compounds give hydrogen bonding interaction between the indolyl CO and CYS919 of the protein active site. Additionally, compounds 6b and 10a-c reveal hydrogen bonding interaction of the indolyl NH with the GLU917 of the protein active site, which is also shown by Sunitinib (co-crystallized ligand in the protein active site). π-Interaction is only revealed by compound 6a. The minor docking score compatibility difference of the docked agents relative to the kinase inhibitory properties observed (Table 3) can be attributed to the effect of environmental conditions applied in the kinase investigation experimental technique, which are not considered in the computational studies.

c-Kit

All the tested compounds (6a–c, 10a–c) show two hydrogen-bonding interactions with CYS673 and GLU671 of the protein active site with alignment similar to that of Sunitinib and varied docking scores. Additionally, all the tested compounds (10b is an exception) support their alignment in the protein active site through π-σ interaction taking place between the indolyl heterocycle and VAL603. Again, the sigh compatibility differences observed due to docking scores and c-kit kinase inhibitory properties of the tested analogues can be attributed to the experimental conditions applied for the biochemical testing which are not considered in the computational work Table 7 (Supplementary Fig. S118).

Generally, the docking studies especially, alignment and hydrogen bonding revealed by the docked agents in the protein active sites, support the multi-targeted kinase inhibitory properties of 6a–c and 10a–c in a comparable behavior to that known by Sunitinib.

Conclusion

In conclusion, 3-alkenyl-2-oxindoles with sulfonate or sulfonamide function seem promising antiproliferative agents. Compounds 6c and 10b are the most effective agents synthesized (about 3.4, 3.3 folds, respectively) against PaCa2 (pancreatic) cancer cell line relative to Sunitinib. Additionally, compound 10b reveals antiproliferative properties against MCF7 (breast) cancer cell line with IC50 close to that of the standard. Meanwhile, compound 6c is the only synthesized analog with cytotoxic properties against HCT116 (colon cancer) cell line close to the standard reference used. CAM testing reveals that compounds 6 and 10 are capable to reduce blood vessel diameter with efficacy comparable to that of Sunitinib supporting their anti-angiogenic properties. Kinase inhibitory properties of the promising antiproliferative 3-alkenyl-2-oxindoles (6a–c, 10a–c) synthesized support their multi-targeted inhibitory activities against VEGFR-2 and c-kit in similar behavior to that of Sunitinib. Molecular docking studies (PDB ID: 4AGD and 3G0E) support these observations. Cell cycle analysis studies utilizing MCF7 (breast) cancer cell, exhibit that compound 6b arrests the cell cycle at G1/S phase while, 10b reveals accumulation of the tested cell at S phase. Additionally, compound 6b is a higher apoptosis performing agent than 10b. Compounds 6a and 10b reveal potent antiviral properties against SARS-CoV-2 with high therapeutical/selectivity index relative to all the standards used (hydroxychloroquine, chloroquine and Favipiravir). The safety profile of the testing agents, especially the high potent ones, against normal cells (VERO-E6 and RPE1) is a good indication for the possibility of utilization as antitumor and/or antiviral agents. Also, the promising results obtained can be adopted for developing higher effective hits.

Experimental

Melting points were determined on a capillary point apparatus (Stuart SMP3) equipped with a digital thermometer. IR spectra (KBr) were recorded on a Shimadzu FT-IR 8400S spectrophotometer. Reactions were monitored using thin layer chromatography (TLC) on 0.2 mm silica gel F254 plates (Merck) utilizing various solvents for elution. The chemical structures of the synthesized compounds were characterized by nuclear magnetic resonance spectra (1H NMR, 13C NMR) and determined on a Bruker NMR spectrometer (500 MHz, 125 MHz for 1H and 13C, respectively). 13C NMR spectra are fully decoupled. Chemical shifts were reported in parts per million (ppm) using the deuterated solvent peak or tetramethylsilane as an internal standard.

Reaction of 4-hydroxyacetophenone (1) and alkane sulfonylchloride 2a,b (general procedure)

A solution of equimolar amounts of the appropriate alkane sulfonylchlorides 2a,b (5 mmol) in dry methylene chloride (5 ml) was added dropwise (10 min.) to the magnetically stirred solution of 4-hydroxyacetophenone 1 in methylene chloride (20 ml) containing triethylamine (5.5 mmol) at 0–5 °C. After complete addition, the reaction with stirred at the same conditions for 3 h and stored at room temperature (20–25 °C) overnight. The reaction mixture was washed with concentrated solution of NaHCO3 (3 × 20 ml) then, with water. The solid separated upon evaporating the reaction mixture till dryness under reduced pressure, was crystallized from methanol affording the corresponding 3a,b as colorless crystals.

4-Acetylphenyl methanesulfonate (3a) [94]

It was obtained from the reaction of 1 and 2a with mp 72–74 °C and yield 98% (1.05 g). IR: ν max/cm−1 1682, 1597, 1501. 1H NMR (DMSO‑d) δ (ppm): 2.61 (s, 3H, H3CCO), 3.47 (s, 3H, H3CS), 7.50 (d, J = 8.7 Hz, 2H, arom. H), 8.08 (d, J = 8.7 Hz, 2H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 26.7 (H3 CCO), 37.7 (H3 CS), 122.3, 130.3, 135.5, 152.3 (arom. C), 196.8 (CO). Anal. Calcd. for C9H10O4S (214.24): C, 50.46; H, 4.71. Found: C, 50.65; H, 4.85.

4-Acetylphenyl ethanesulfonate (3b)

It was obtained from the reaction of 1 and 2b with mp 63–65 °C and yield 89% (1.02 g). IR: ν max/cm−1 1678, 1593, 1497. 1H NMR (DMSO‑d) δ (ppm): 1.41 (t, J = 7.4 Hz, 3H, HH2CS), 2.60 (s, 3H, H3CCO), 3.60 (q, J = 7.4 Hz, 2H, H2CS), 7.48 (d, J = 8.7 Hz, 2H, arom. H), 8.07 (d, J = 8.7 Hz, 2H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 8.0 (H3 CH2CS), 26.7 (H3 CCO), 45.1 (H2 CS), 122.2, 130.4, 135.5, 152.2 (arom. C), 196.8 (CO). Anal. Calcd. for C10H12O4S (228.26): C, 52.62; H, 5.30. Found: C, 52.73; H, 5.46.

Reaction of 3a,b with 4a,b (general procedure)

A mixture of equimolar amounts of the appropriate isatin 4a,b (5 mmol) and the corresponding acetophenone 3a,b in ethanol absolute (15 ml) containing quantitative amount of diethylamine was stirred at room temperature (20–25 °C) for the appropriate time. The separated solid 5a-d was collected washed with benzene (10 ml) and used in the next step without any more purification.

4-[2-(3-Hydroxy-2-oxoindolin-3-yl)acetyl]phenyl methanesulfonate (5a)

It was obtained from the reaction of 3a and 4a as colorless solid, reaction time 48 h, with mp 159–161 °C and yield 73% (1.31 g). IR: ν max/cm−1 3291, 1701, 1675, 1616, 1601. 1H NMR (DMSO‑d) δ (ppm): 3.44 (s, 3H, SCH3), 3.61 (d, J = 17.5 Hz, 1H upfield H of CH2CO), 4.09 (d, J = 17.5 Hz, 1H, downfield H of CH2CO), 6.11 (s, 1H, OH), 6.82 (d, J = 7.7 Hz, 1H, arom. H), 6.87 (t, J = 7.4 Hz, 1H, arom. H), 7.17 (t, J = 7.6 Hz, 1H, arom. H), 7.29 (d, J = 7.3 Hz, 1H, arom. H), 7.47 (d, J = 8.7 Hz, 2H, arom. H), 8.02 (d, J = 8.7 Hz, 2H, arom. H), 10.29 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 37.6 (SCH3), 45.7 (CH2CO), 72.9 (indolyl C-3), 109.3, 121.1, 122.3, 123.5, 128.9, 130.1, 131.5, 134.8, 142.8, 152.4 (arom. C), 178.2 [indolyl CO (C-2)], 195.4 (ketonic CO). Anal. Calcd. for C17H15NO6S (361.37): C, 56.50; H, 4.18; N, 3.88. Found: C, 56.59; H, 4.31; N, 4.02.

4-[2-(5-Chloro-3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl methanesulfonate (5b)

It was obtained from the reaction of 3a and 4b as colorless solid, reaction time 24 h, with mp 195–197 °C and yield 92% (1.82 g). IR: ν max/cm−1 3217, 1697, 1625, 1597. 1H NMR (DMSO‑d) δ (ppm): 3.45 (s, 3H, SCH3), 3.67 (d, J = 17.9 Hz, 1H upfield H of CH2CO), 4.18 (d, J = 17.9 Hz, 1H, downfield H of CH2CO), 6.26 (s, 1H, OH), 6.85 (d, J = 8.3 Hz, 1H, arom. H), 7.23 (dd, J = 2.0, 8.2 Hz, 1H, arom. H), 7.41 (d, J = 1.8 Hz, 1H, arom. H), 7.49 (d, J = 8.6 Hz, 2H, arom. H), 8.03 (d, J = 8.7 Hz, 2H, arom. H), 10.44 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 37.6 (SCH3), 45.7 (CH2CO), 73.0 (indolyl C-3), 110.8, 122.3, 123.9, 125.1, 128.6, 130.2, 133.7, 134.6, 141.8, 152.5 (arom. C), 177.9 [indolyl CO (C-2)], 195.5 (ketonic CO). Anal. Calcd. for C17H14ClNO6S (395.81): C, 51.59; H, 3.57; N, 3.54. Found: C, 51.79; H, 3.72; N, 3.70.

4-[2-(3-Hydroxy-2-oxoindolin-3-yl)acetyl]phenyl ethanesulfonate (5c)

It was obtained from the reaction of 3b and 4a as colorless solid, reaction time 24 h, with mp 156–158 °C and yield 80% (1.50 g). IR: ν max/cm−1 3306, 1709, 1678, 1618, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.38 (t, J = 7.1 Hz, 3H, HH2CS), 3.58 (q, J = 7.1 Hz, 2H, SCH2), 3.61 (d, J = 17.2 Hz, 1H upfield H of CH2CO), 4.09 (d, J = 17.5 Hz, 1H, downfield H of CH2CO), 6.12 (s, 1H, OH), 6.83 (d, J = 7.6 Hz, 1H, arom. H), 6.87 (t, J = 7.4 Hz, 1H, arom. H), 7.17 (t, J = 7.4 Hz, 1H, arom. H), 7.29 (d, J = 7.1 Hz, 1H, arom. H), 7.45 (d, J = 8.2 Hz, 2H, arom. H), 8.02 (d, J = 8.3 Hz, 2H, arom. H), 10.30 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 8.1 (H3 CH2CS), 45.1 (SCH2), 45.9 (CH2CO), 73.1 (indolyl C-3), 109.6, 121.3, 122.4, 123.7, 129.1, 130.3, 131.7, 134.9, 143.0, 152.4 (arom. C), 178.4 [indolyl CO (C-2)], 195.5 (ketonic CO). Anal. Calcd. for C18H17NO6S (375.40): C, 57.59; H, 4.56; N, 3.73. Found: C, 57.47; H, 4.75; N, 3.84.

4-[2-(5-Chloro-3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl ethanesulfonate (5d)

It was obtained from the reaction of 3b and 4b as colorless solid, reaction time 24 h, with mp 171–173 °C and yield 86% (1.75 g). IR: ν max/cm−1 3244, 1701, 1690, 1620, 1597. 1H NMR (DMSO‑d) δ (ppm): 1.39 (t, J = 7.3 Hz, 3H, HH2CS), 3.59 (q, J = 7.3 Hz, 2H, SCH2), 3.68 (d, J = 17.9 Hz, 1H upfield H of CH2CO), 4.19 (d, J = 17.9 Hz, 1H, downfield H of CH2CO), 6.27 (s, 1H, OH), 6.86 (d, J = 8.3 Hz, 1H, arom. H), 7.24 (dd, J = 2.1, 8.3 Hz, 1H, arom. H), 7.42 (d, J = 2.0 Hz, 1H, arom. H), 7.47 (d, J = 8.7 Hz, 2H, arom. H), 8.03 (d, J = 8.7 Hz, 2H, arom. H), 10.45 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 8.0 (H3 CH2CS), 45.0 (SCH2), 45.7 (CH2CO), 73.0 (indolyl C-3), 110.8, 122.2, 124.0, 125.2, 128.6, 130.2, 133.8, 134.5, 141.8, 152.4 (arom. C), 177.9 [indolyl CO (C-2)], 195.4 (ketonic CO). Anal. Calcd. for C18H16ClNO6S (409.84): C, 52.75; H, 3.94; N, 3.42. Found: C, 52.88; H, 4.14; N, 3.54.

Acidic dehydration of 5 (general procedure)

Hydrochloric acid (25 ml, 25%) was added dropwise (10 min.) to a magnetically stirred solution of 5 (5 mmol) in absolute ethanol (12.5 ml) at room temperature (20–25 °C) for the appropriate time. The separated solid was collected, washed with water and purified by crystallization from a suitable solvent affording the corresponding 6a,b; and chromatographic tool (silica gel TLC) giving 6c.

(E)-4-[2-(2-Oxoindolin-3-ylidene)acetyl]phenyl methanesulfonate (6a)

It was obtained from acidic dehydration of 5a for 72 h as red microcrystals from n-butanol with mp 222–224 °C and yield 86% (1.47 g). IR: ν max/cm−1 3352, 1721, 1659, 1601. 1H NMR (DMSO‑d) δ (ppm): 3.51 (s, 3H, SCH3), 6.91 (d, J = 7.8 Hz, 1H, arom. H), 6.98 (t, J = 7.7 Hz, 1H, arom. H), 7.37 (t, J = 7.7 Hz, 1H, arom. H), 7.59 (d, J = 8.6 Hz, 2H, arom. H), 7.74 (s, 1H, olefinic CH), 8.09 (d, J = 7.7 Hz, 1H, arom. H), 8.21 (d, J = 8.6 Hz, 2H, arom. H), 10.83 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 37.8 (SCH3), 110.3, 119.9, 121.7, 122.8, 125.3, 126.8, 130.8, 133.1, 135.8, 136.8, 145.0, 152.7 (arom. C), 168.1 [indolyl CO (C-2)], 190.0 (ketonic CO). Anal. Calcd. for C17H13NO5S (343.35): C, 59.47; H, 3.82; N, 4.08. Found: C, 59.29; H, 3.66 N, 3.95.

(E)-4-[2-(2-Oxoindolin-3-ylidene)acetyl]phenyl ethanesulfonate (6b)

It was obtained from acidic dehydration of 5c for 72 h as red microcrystals from methanol with mp 166–170 °C and yield 75% (1.34 g). IR: ν max/cm−1 3159, 1713, 1659, 1620. 1H NMR (DMSO‑d) δ (ppm): 1.41 (t, J = 7.3 Hz, 3H, CH3), 3.63 (q, J = 7.4 Hz, 2H, SCH2), 6.90 (d, J = 7.8 Hz, 1H, arom. H), 6.97 (t, J = 7.7 Hz, 1H, arom. H), 7.36 (t, J = 7.7 Hz, 1H, arom. H), 7.55 (d, J = 8.8 Hz, 2H, arom. H), 7.72 (s, 1H, olefinic CH), 8.07 (d, J = 7.8 Hz, 1H, arom. H), 8.20 (d, J = 8.7 Hz, 2H, arom. H), 10.82 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 8.0 (CH3), 45.1 (SCH2), 110.3, 119.8, 121.7, 122.6, 125.3, 126.8, 130.8, 133.0, 135.7, 136.7, 145.0, 152.6 (arom. C), 168.1 [indolyl CO (C-2)], 189.9 (ketonic CO). Anal. Calcd. for C18H15NO5S (357.38): C, 60.50; H, 4.23; N, 3.92. Found: C, 60.39H, 4.31; N, 3.73.

(E)-4-[2-(5-Chloro-2-oxoindolin-3-ylidene)acetyl]phenyl ethanesulfonate (6c)

It was obtained from acidic dehydration of 5d for 72 h as red microcrystals purified by silica gel TLC (60 G, F254 glass plate) using CH2Cl2 for elution, with mp 180–182 °C and yield 77% (1.51 g). IR: ν max/cm−1 3179, 1713, 1659, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.41 (t, J = 7.3 Hz, 3H, CH3), 3.64 (q, J = 7.3 Hz, 2H, SCH2), 6.91 (d, J = 8.3 Hz, 1H, arom. H), 7.42 (dd, J = 2.1, 8.3 Hz, 1H, arom. H), 7.56 (d, J = 8.7 Hz, 2H, arom. H), 7.80 (s, 1H, olefinic CH), 8.17 (d, J = 1.9 Hz, 1H, arom. H), 8.21 (d, J = 8.7 Hz, 2H, arom. H), 10.96 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 8.0 (CH3), 45.1 (SCH2), 111.8, 121.3, 122.6, 125.5, 126.4, 131.0, 132.5, 135.6, 136.2, 143.9, 152.7 (arom. C), 167.8 [indolyl CO (C-2)], 189.5 (ketonic CO). Anal. Calcd. for C18H14ClNO5S (391.82): C, 55.18; H, 3.60; N, 3.57. Found: C, 55.33; H, 3.73; N, 3.51.

Reaction of 4-aminoacetophenone (7) and alkane sulfonylchloride 2a-c (general procedure)

A solution of the appropriate alkane sulfonylchlorides 2a-c (10 mmol in case of 2a,b and 5 mmol in case of 2c) in dry methylene chloride (5 ml) was added dropwise (10 min.) to the magnetically stirred solution of 4-aminoacetophenone 7 (5 mmol) in methylene chloride (20 ml) containing triethylamine (11 mmol in case of 2a,b and 5.5 mmol in case of 2c) at 0–5 °C. After complete addition, the reaction with stirred at the same conditions for 3 h and stored at room temperature (20–25 °C) overnight. The reaction mixture was washed with concentrated solution of NaHCO3 (3 × 20 ml) then, with water. The solid separated upon evaporation the reaction mixture till dryness under reduced pressure, was collected and crystallized from a suitable solvent affording the corresponding 8a-c as colorless crystals.

N-(4-Acetylphenyl)-N-(methylsulfonyl)methanesulfonamide (8a)

It was obtained from the reaction of 7 and 2a as colorless microcrystals from n-butanol with mp 172–174 °C and yield 82% (1.20 g). IR: ν max/cm−1 1682, 1597, 1504. 1H NMR (DMSO‑d) δ (ppm): 2.63 (s, 3H, H3CCO), 3.57 (s, 6H, 2 SCH3), 7.69 (d, J = 8.5 Hz, 2H, arom. H), 8.04 (d, J = 8.4 Hz, 2H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 26.9 (H3 CCO), 43.1 (H3 CS), 129.1, 131.2, 137.7 (arom. C), 197.2 (CO). Anal. Calcd. for C10H13NO5S2 (291.34): C, 41.23; H, 4.50; N, 4.81. Found: C, 41.13; H, 4.43; N, 4.66.

N-(4-Acetylphenyl)-N-(ethylsulfonyl)ethanesulfonamide (8b)

It was obtained from the reaction of 7 and 2b as colorless microcrystals from benzene – pet. ether (60–80 °C) mixture as 1:3 v/v with mp 118–120 °C and yield 88% (1.40 g). IR: ν max/cm−1 1682, 1597, 1501. 1H NMR (DMSO‑d) δ (ppm): 1.36 (t, J = 7.4 Hz, 6H, 2 HH2CS), 2.63 (s, 3H, H3CCO), 3.70 (q, J = 7.3 Hz, 4H, 2 SCH2), 7.66 (d, J = 8.3 Hz, 2H, arom. H), 8.05 (d, J = 8.3 Hz, 2H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 7.7 (H3 CH2CS), 26.9 (H3 CCO), 49.9 (SCH2), 129.2, 131.8, 137.7 (arom. C), 197.3 (CO). Anal. Calcd. for C12H17NO5S2 (319.39): C, 45.13; H, 5.37; N, 4.39. Found: C, 45.07; H, 5.40; N, 4.29.

N-(4-Acetylphenyl)propane-1-sulfonamide (8c)

It was obtained from the reaction of 7 and 2c as colorless microcrystals from methanol with mp 125–127 °C and yield 92% (1.11 g). IR: ν max/cm−1 3252, 3213, 1670, 1601, 1578. 1H NMR (DMSO‑d) δ (ppm): 0.94 (t, J = 7.5 Hz, 3H, HH2CH2CS), 1.69 (sextet, J = 7.4 Hz, 2H, HH2CS), 2.52 (s, 3H, H3CCO), 3.18 (t, J = 7.6 Hz, 2H, SCH2), 7.30 (d, J = 8.7 Hz, 2H, arom. H), 7.93 (d, J = 8.7 Hz, 2H, arom. H), 10.33 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 12.4 (H3 CH2CH2CS), 16.8 (H2 CH2CS), 26.3 (H3 CCO), 52.8 (SCH2), 117.3, 129.9, 131.5, 143.0 (arom. C), 196.4 (CO). Anal. Calcd. for C11H15NO3S (241.31): C, 54.75; H, 6.27; N, 5.80. Found: C, 54.58; H, 6.46; N, 5.74.

Reaction of 8a-c with 4a-c (general procedure)

A mixture of equimolar amounts of the appropriate isatin 4a-c (5 mmol) and the corresponding acetophenone 8a-c in ethanol absolute (15 ml) containing quantitative amount of diethylamine was stirred at room temperature (20–25 °C) for the appropriate time. The separated solid 9a–g was collected washed with benzene (10 ml) and used in the next step without any more purification.

N-{4-[2-(3-Hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(methylsulfonyl)methanesulfonamide (9a)

It was obtained from the reaction of 8a and 4a as colorless solid, reaction time 48 h, with mp 209–211 °C and yield 72% (1.57 g). IR: ν max/cm−1 3410, 1701, 1682, 1620, 1601. 1H NMR (DMSO‑d) δ (ppm): 3.56 (s, 6H, 2 SCH3), 3.63 (d, J = 17.6 Hz, 1H upfield H of CH2CO), 4.11 (d, J = 17.6 Hz, 1H, downfield H of CH2CO), 6.10 (s, 1H, OH), 6.82 (d, J = 7.7 Hz, 1H, arom. H), 6.86 (t, J = 7.5 Hz, 1H, arom. H), 7.17 (t, J = 7.7 Hz, 1H, arom. H), 7.29 (d, J = 7.3 Hz, 1H, arom. H), 7.66 (d, J = 8.4 Hz, 2H, arom. H), 7.99 (d, J = 8.4 Hz, 2H, arom. H), 10.29 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 43.0 (SCH3), 45.8 (CH2CO), 72.9 (indolyl C-3), 109.3, 121.1, 123.6, 128.9, 129.0, 131.2, 131.5, 137.0, 137.9, 142.8 (arom. C), 178.1 [indolyl CO (C-2)], 195.8 (ketonic CO). Anal. Calcd. for C18H18N2O7S2 (438.47): C, 49.31; H, 4.14; N, 6.39. Found: C, 49.51; H, 4.28; N, 6.55.

N-{4-[2-(5-Chloro-3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(methylsulfonyl)methanesulfonamide (9b)

It was obtained from the reaction of 8a and 4b as colorless solid, reaction time 72 h, with mp 208–210 °C and yield 69% (1.64 g). IR: ν max/cm−1 3337, 1724, 1694, 1621, 1601. 1H NMR (DMSO‑d) δ (ppm): 3.57 (s, 6H, 2 SCH3), 3.70 (d, J = 18.0 Hz, 1H upfield H of CH2CO), 4.21 (d, J = 18.1 Hz, 1H, downfield H of CH2CO), 6.26 (s, 1H, OH), 6.85 (d, J = 8.3 Hz, 1H, arom. H), 7.24 (dd, J = 2.1, 8.3 Hz, 1H, arom. H), 7.42 (d, J = 2.1 Hz, 1H, arom. H), 7.69 (d, J = 8.5 Hz, 2H, arom. H), 8.00 (d, J = 8.5 Hz, 2H, arom. H), 10.44 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 43.1 (SCH3), 45.7 (CH2CO), 72.9 (indolyl C-3), 110.7, 117.3, 123.9, 125.1, 128.6, 129.0, 129.7, 131.2, 133.7, 136.8, 138.0, 141.8 (arom. C), 177.9 [indolyl CO (C-2)], 195.9 (ketonic CO). Anal. Calcd. for C18H17ClN2O7S2 (472.91): C, 45.72; H, 3.62; N, 5.92. Found: C, 45.81; H, 3.78; N, 6.06.

N-(Ethylsulfonyl)-N-{4-[2-(3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}ethanesulfonamide (9c)

It was obtained from the reaction of 8b and 4a as colorless solid, reaction time 48 h, with mp 204–206 °C and yield 67% (1.56 g). IR: ν max/cm−1 3402, 3198, 1697, 1682, 1620, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.34 (t, J = 7.3 Hz, 6H, 2 CH3), 3.63 (d, J = 17.6 Hz, 1H, upfield H of CH2CO), 3.68 (q, J = 7.4 Hz, 4H, 2 SCH2), 4.12 (d, J = 17.6 Hz, 1H, downfield H of CH2CO), 6.12 (s, 1H, OH), 6.84 (d, J = 7.7 Hz, 1H, arom. H), 6.88 (t, J = 7.5 Hz, 1H, arom. H), 7.18 (t, J = 7.7 Hz, 1H, arom. H), 7.31 (d, J = 7.3 Hz, 1H, arom. H), 7.63 (d, J = 8.5 Hz, 2H, arom. H), 8.00 (d, J = 8.4 Hz, 2H, arom. H), 10.30 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 7.6 (CH3), 45.8 (CH2CO), 49.8 (SCH2), 72.9 (indolyl C-3), 109.3, 121.1, 123.6, 128.9, 131.5, 131.7, 137.0, 137.7, 142.8 (arom. C), 178.1 [indolyl CO (C-2)], 195.8 (ketonic CO). Anal. Calcd. for C20H22N2O7S2 (466.52): C, 51.49; H, 4.75; N, 6.00. Found: C, 51.60; H, 4.82; N, 6.05.

N-{4-[2-(5-Chloro-3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(ethylsulfonyl)ethanesulfonamide (9d)

It was obtained from the reaction of 8b and 4b as colorless solid, reaction time 72 h, with mp 191–193 °C and yield 66% (1.66 g). IR: ν max/cm−1 3252, 1695, 1682, 1620, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.34 (t, J = 7.3 Hz, 6H, 2 CH3), 3.66–3.71 (m, 5H, 2 SCH2 + upfield H of CH2CO), 4.20 (d, J = 18.0 Hz, 1H, downfield H of CH2CO), 6.27 (s, 1H, OH), 6.85 (d, J = 8.2 Hz, 1H, arom. H), 7.24 (dd, J = 1.6, 8.2 Hz, 1H, arom. H), 7.42 (d, J = 1.1 Hz, 1H, arom. H), 7.64 (d, J = 8.3 Hz, 2H, arom. H), 8.00 (d, J = 8.3 Hz, 2H, arom. H), 10.45 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 7.7 (CH3), 45.8 (CH2CO), 49.9 (SCH2), 73.0 (indolyl C-3), 110.8, 124.0, 125.2, 128.7, 129.0, 131.8, 133.8, 136.8, 138.0, 141.9 (arom. C), 178.0 [indolyl CO (C-2)], 196.0 (ketonic CO). Anal. Calcd. for C20H21ClN2O7S2 (500.97): C, 47.95; H, 4.23; N, 5.59. Found: C, 48.13; H, 4.36; N, 5.78.

N-{4-[2-(3-Hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(propylsulfonyl)propane-1-sulfonamide (9e)

It was obtained from the reaction of 8c and 4a as colorless solid, reaction time 48 h, with mp 191–193 °C and yield 39% (0.96 g). IR: ν max/cm−1 3422, 3256, 1740, 1678, 1624, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.00 (t, J = 7.4 Hz, 6H, 2 CH3), 1.80 (sextet, J = 7.4 Hz, 4H, 2 SCH2 CH), 3.61 (d, J = 17.9 Hz, 1H upfield H of CH2CO), 3.65 (t, J = 7.6 Hz, 4H, 2 SCH2), 4.10 (d, J = 17.7 Hz, 1H, downfield H of CH2CO), 6.09 (s, 1H, OH), 6.82 (d, J = 7.7 Hz, 1H, arom. H), 6.86 (t, J = 7.5 Hz, 1H, arom. H), 7.17 (t, J = 7.6 Hz, 1H, arom. H), 7.29 (d, J = 7.2 Hz, 1H, arom. H), 7.61 (d, J = 8.4 Hz, 2H, arom. H), 7.98 (d, J = 8.4 Hz, 2H, arom. H), 10.28 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 12.4 (CH3), 16.5 (SCH2 CH2), 45.8 (CH2CO), 56.6 (SCH2), 72.9 (indolyl C-3), 109.3, 121.0, 123.6, 128.9, 131.5, 131.7, 137.0, 137.7, 142.8 (arom. C), 178.1 [indolyl CO (C-2)], 195.8 (ketonic CO). Anal. Calcd. for C22H26N2O7S2 (494.58): C, 53.43; H, 5.30; N, 5.66. Found: C, 53.24; H, 5.41; N, 5.72.

N-{4-[2-(5-Chloro-3-hydroxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(propylsulfonyl)propane-1-sulfonamide (9f)

It was obtained from the reaction of 8c and 4b as colorless solid, reaction time 72 h, with mp 179–181 °C and yield 46% (1.21 g). IR: ν max/cm−1 3356, 3256, 1721, 1682, 1620, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.02 (t, J = 7.4 Hz, 6H, 2 CH3), 1.83 (sextet, J = 7.4 Hz, 4H, 2 SCH2 CH), 3.67 (t, J = 7.7 Hz, 4H, 2 SCH2), 3.71 (d, J = 18.9 Hz, 1H upfield H of CH2CO), 4.22 (d, J = 18.0 Hz, 1H, downfield H of CH2CO), 6.28 (s, 1H, OH), 6.87 (d, J = 8.3 Hz, 1H, arom. H), 7.25 (dd, J = 1.9, 8.3 Hz, 1H, arom. H), 7.43 (br s, 1H, arom. H), 7.65 (d, J = 8.4 Hz, 2H, arom. H), 8.01 (d, J = 8.4 Hz, 2H, arom. H), 10.46 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 13.0 (CH3), 17.1 (SCH2 CH2), 46.3 (CH2CO), 57.2 (SCH2), 73.5 (indolyl C-3), 111.3, 124.5, 125.7, 128.8, 129.2, 129.5, 132.3, 134.3, 137.3, 138.4, 142.4 (arom. C), 178.4 [indolyl CO (C-2)], 196.4 (ketonic CO). Anal. Calcd. for C22H25ClN2O7S2 (529.02): C, 49.95; H, 4.76; N, 5.30. Found: C, 50.08; H, 4.92; N, 5.39.

N-{4-[2-(3-Hydroxy-5-methoxy-2-oxoindolin-3-yl)acetyl]phenyl}-N-(propylsulfonyl)propane-1-sulfonamide (9 g)

It was obtained from the reaction of 8c and 4c as colorless solid, reaction time 72 h, with mp 161–163 °C and yield 44% (1.14 g). IR: ν max/cm−1 3348, 1717, 1686, 1605. 1H NMR (DMSO‑d) δ (ppm): 1.02 (t, J = 7.4 Hz, 6H, 2 CH3), 1.82 (sextet, J = 7.3 Hz, 4H, 2 SCH2 CH), 3.60–3.68 (m, 8H, 2 SCH2 + OCH3 + upfield H of CH2CO), 4.12 (d, J = 17.6 Hz, 1H, downfield H of CH2CO), 6.12 (s, 1H, OH), 6.75 (br s, 2H, arom. H), 7.00 (br s, 1H, arom. H), 7.64 (d, J = 8.3 Hz, 2H, arom. H), 8.00 (d, J = 8.3 Hz, 2H, arom. H), 10.13 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 12.4 (CH3), 16.5 (SCH2 CH2), 45.8 (CH2CO), 55.3 (OCH3), 56.6 (SCH2), 73.4 (indolyl C-3), 109.6, 110.9, 113.3, 128.9, 131.7, 132.8, 136.0, 137.0, 137.7, 154.6 (arom. C), 178.1 [indolyl CO (C-2)], 195.8 (ketonic CO). Anal. Calcd. for C23H28N2O8S2 (524.60): C, 52.66; H, 5.38; N, 5.34. Found: C, 52.82; H, 5.46; N, 5.51.

Acidic dehydration of 9 (general procedure)

Hydrochloric acid (25 ml, 25%) was added dropwise (10 min.) to a magnetically stirred solution of 9 (5 mmol) in absolute ethanol (12.5 ml) at room temperature (20–25 °C) for the appropriate time. The separated solid was collected, washed with water and crystallized from a suitable solvent affording the corresponding 10.

(E)-N-(Methylsulfonyl)-N-{4-[2-(2-oxoindolin-3-ylidene)acetyl]phenyl}methanesulfonamide (10a)

It was obtained from acidic dehydration of 9a for 72 h as red microcrystals from methanol with mp 239–241 °C and yield 66% (1.39 g). IR: ν max/cm−1 3194, 1717, 1663, 1505. 1H NMR (DMSO‑d) δ (ppm): 3.61 (s, 6H, 2 SCH3), 6.91 (d, J = 7.8 Hz, 1H, arom. H), 6.98 (t, J = 7.7 Hz, 1H, arom. H), 7.37 (t, J = 7.7 Hz, 1H, arom. H), 7.75 (s, 1H, olefinic CH), 7.79 (d, J = 8.5 Hz, 2H, arom. H), 8.11 (d, J = 7.7 Hz, 1H, arom. H), 8.18 (d, J = 8.5 Hz, 2H, arom. H), 10.83 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 43.1 (SCH3), 110.3, 119.8, 121.7, 125.3, 126.8, 129.6, 131.6, 133.1, 137.0, 138.16, 138.23, 145.1 (arom. C + olefinic C), 168.1 [indolyl CO (C-2)], 190.4 (ketonic CO). Anal. Calcd. for C18H16N2O6S2 (420.45): C, 51.42; H, 3.84; N, 6.66. Found: C, 51.31; H, 3.71; N, 6.56.

(E)-N-(Ethylsulfonyl)-N-{4-[2-(2-oxoindolin-3-ylidene)acetyl]phenyl}ethanesulfonamide (10b)

It was obtained from acidic dehydration of 9c for 72 h as red microcrystals from methanol with mp 220–222 °C and yield 70% (1.56 g). IR: ν max/cm−1 3395, 3159, 1717, 1663, 1605. 1H NMR (DMSO‑d) δ (ppm): 1.36 (t, J = 7.4 Hz, 6H, 2 CH3), 3.71 (q, J = 7.4 Hz, 4H, 2 SCH2), 6.90 (d, J = 7.8 Hz, 1H, arom. H), 6.98 (t, J = 7.6 Hz, 1H, arom. H), 7.37 (t, J = 7.7 Hz, 1H, arom. H), 7.73 (d, J = 7.8 Hz, 2H, arom. H), 7.74 (s, 1H, olefinic CH), 8.10 (d, J = 7.7 Hz, 1H, arom. H), 8.17 (d, J = 8.5 Hz, 2H, arom. H), 10.83 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 7.6 (CH3), 49.9 (SCH2), 110.3, 119.8, 121.7, 125.3, 126.8, 129.5, 132.1, 133.2, 136.9, 138.1, 145.1 (arom. C + olefinic C), 168.1 [indolyl CO (C-2)], 190.3 (ketonic CO). Anal. Calcd. for C20H20N2O6S2 (448.51): C, 53.56; H, 4.49; N, 6.25. Found: C, 53.42; H, 4.42; N, 6.11.

(E)-N-{4-[2-(5-Chloro-2-oxoindolin-3-ylidene)acetyl]phenyl}-N-(ethylsulfonyl)ethanesulfonamide (10c)

It was obtained from acidic dehydration of 9d for 72 h as red microcrystals from methanol with mp 222–224 °C and yield 77% (1.85 g). IR: ν max/cm−1 3171, 1717, 1663, 1601. 1H NMR (DMSO‑d) δ (ppm): 1.37 (t, J = 7.3 Hz, 6H, 2 CH3), 3.72 (q, J = 7.2 Hz, 4H, 2 SCH2), 6.89 (d, J = 8.3 Hz, 1H, arom. H), 7.40 (dd, J = 1.6, 8.3 Hz, 1H, arom. H), 7.74 (d, J = 8.3 Hz, 2H, arom. H), 7.80 (s, 1H, olefinic CH), 8.18 (d, J = 8.6 Hz, 2H, arom. H), 8.19 (d, J = 2.0 Hz, 1H, arom. H), 10.95 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 7.6 (CH3), 49.9 (SCH2), 111.8, 121.3, 125.6, 126.3, 126.5, 129.6, 132.1, 132.6, 136.4, 138.1, 138.2, 144.0 (arom. C + olefinic C), 167.8 [indolyl CO (C-2)], 189.9 (ketonic CO). Anal. Calcd. for C20H19ClN2O6S2 (482.95): C, 49.74; H, 3.97; N, 5.80. Found: C, 49.55; H, 3.86; N, 5.73.

Reaction of 4a-e with 11a,b (general procedure)

A mixture of equimolar amounts of the appropriate isatin 4a-e (5 mmol) and the corresponding 2-acetylbenzimidazole 11a,b [95], [96] in ethanol absolute (15 ml) containing quantitative amount of diethylamine was stirred at room temperature (20–25 °C) for 3 h. The reaction mixture was stored at room temperature overnight, the separated solid 12a–h was collected washed with benzene (10 ml) and used in the next step without any more purification.

3-Hydroxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]indolin-2-one (12a)

It was obtained from the reaction of 4a and 11a as colorless solid with mp 139–141 °C and yield 84% (1.35 g). IR: ν max/cm−1 3568, 3302, 3213, 1709, 1690, 1678, 1628, 1612. 1H NMR (DMSO‑d) δ (ppm): 3.73 (d, J = 17.1 Hz, 1H upfield H of CH2CO), 3.84 (s, 3H, NCH3), 4.36 (d, J = 17.1 Hz, 1H, downfield H of CH2CO), 6.29 (s, 1H, OH), 6.85 (t, J = 7.8 Hz, 2H, arom. H), 7.17 (t, J = 7.5 Hz, 1H, arom. H), 7.30 (d, J = 7.2 Hz, 1H, arom. H), 7.34 (t, J = 7.6 Hz, 1H, arom. H), 7.41 (t, J = 7.6 Hz, 1H, arom. H), 7.61 (d, J = 8.1 Hz, 1H, arom. H), 7.83 (d, J = 8.1 Hz, 1H, arom. H), 10.36 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 31.9 (NCH3), 46.8 (CH2CO), 73.2 (indolyl C-3) 109.6, 111.6, 121.2, 121.4, 123.6, 123.9, 125.8, 129.2, 131.4, 136.7, 140.8, 142.7, 145.6 (arom. C), 178.1 [indolyl CO (C-2)], 191.3 (ketonic CO). Anal. Calcd. for C18H15N3O3 (321.34): C, 67.28; H, 4.71; N, 13.08. Found: C, 67.18; H, 4.57; N, 12.92.

3-[2-(1-Ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]-3-hydroxyindolin-2-one (12b)

It was obtained from the reaction of 4a and 11b as colorless solid with mp 134–136 °C and yield 74% (1.24 g). IR: ν max/cm−1 3595, 3306, 3213, 1710, 1690, 1686, 1624. 1H NMR (DMSO‑d) δ (ppm): 1.09 (t, J = 6.6 Hz, 3H, CH3), 3.69 (d, J = 16.6 Hz, 1H upfield H of CH2CO), 4.38 (br d, 3H, NCHCH3 + downfield H of CH2CO), 6.29 (s, 1H, OH), 6.82–6.83 (m, 2H, arom. H), 7.15 (t, J = 7.5 Hz, 1H, arom. H), 7.27 (d, J = 7.0 Hz, 1H, arom. H), 7.35 (t, J = 7.3 Hz, 1H, arom. H), 7.43 (t, J = 7.3 Hz, 1H, arom. H), 7.66 (d, J = 8.2 Hz, 1H, arom. H), 7.85 (d, J = 8.1 Hz, 1H, arom. H), 10.35 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 15.2 (CH3), 39.8 (NCH2CH3), 46.7 (CH2CO), 73.3 (indolyl C-3) 109.6, 111.5, 121.3, 121.4, 123.7, 123.9, 125.9, 129.2, 131.2, 135.8, 141.0, 142.6, 145.1 (arom. C), 178.1 [indolyl CO (C-2)], 191.3 (ketonic CO). Anal. Calcd. for C19H17N3O3 (335.36): C, 68.05; H, 5.11; N, 12.53. Found: C, 68.21; H, 5.02; N, 12.67.

5-Chloro-3-hydroxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]indolin-2-one (12c)

It was obtained from the reaction of 4b and 11a as colorless solid with mp 186–188 °C and yield 71% (1.26 g). IR: ν max/cm−1 3348, 3298, 1717, 1686, 1670, 1624. 1H NMR (DMSO‑d) δ (ppm): 3.82 (d, J = 17.7 Hz, 1H upfield H of CH2CO), 3.88 (s, 3H, NCH3), 4.36 (d, J = 17.6 Hz, 1H, downfield H of CH2CO), 6.39 (s, 1H, OH), 6.85 (d, J = 8.2 Hz, 1H, arom. H), 7.23 (d, J = 8.1 Hz, 1H, arom. H), 7.35 (t, J = 7.4 Hz, 1H, arom. H), 7.40–7.44 (m, 2H, arom. H), 7.64 (d, J = 8.1 Hz, 1H, arom. H), 7.84 (d, J = 8.1 Hz, 1H, arom. H), 10.50 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 32.0 (NCH3), 46.7 (CH2CO), 73.1 (indolyl C-3) 111.0, 111.6, 121.2, 123.6, 124.3, 125.4, 125.8, 128.9, 133.5, 136.7, 140.8, 141.6, 145.4 (arom. C), 177.8 [indolyl CO (C-2)], 191.3 (ketonic CO). Anal. Calcd. for C18H14ClN3O3 (355.78): C, 60.77; H, 3.97; N, 11.81. Found: C, 61.06; H, 4.09; N, 11.99.

5-Chloro-3-[2-(1-ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]-3-hydroxyindolin-2-one (12d)

It was obtained from the reaction of 4b and 11b as colorless solid with mp 169–171 °C and yield 75% (1.38 g). IR: ν max/cm−1 3464, 3256, 1740, 1701, 1686, 1620. 1H NMR (DMSO‑d) δ (ppm): 1.13 (t, J = 6.5 Hz, 3H, CH3), 3.80 (d, J = 17.2 Hz, 1H upfield H of CH2CO), 4.35–4.41 (m, 3H, NCHCH3 + downfield H of CH2CO), 6.41 (s, 1H, OH), 6.84 (d, J = 8.1 Hz, 1H, arom. H), 7.22 (d, J = 8.2 Hz, 1H, arom. H), 7.34–7.38 (m, 2H, arom. H), 7.43 (t, J = 7.3 Hz, 1H, arom. H), 7.67 (d, J = 8.1 Hz, 1H, arom. H), 7.86 (d, J = 8.1 Hz, 1H, arom. H), 10.50 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 15.2 (CH3), 39.8 (NCH2CH3), 46.7 (CH2CO), 73.3 (indolyl C-3) 111.0, 111.5, 121.4, 123.7, 124.3, 125.4, 125.9, 128.9, 133.4, 135.7, 141.0, 141.6, 144.9 (arom. C), 177.8 [indolyl CO (C-2)], 191.2 (ketonic CO). Anal. Calcd. for C19H16ClN3O3 (369.81): C, 61.71; H, 4.36; N, 11.36. Found: C, 61.85; H, 4.42; N, 11.45.

3-Hydroxy-5-methoxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]indolin-2-one (12e)

It was obtained from the reaction of 4c and 11a as colorless solid with mp 174–176 °C and yield 78% (1.37 g). IR: ν max/cm−1 3186, 1724, 1686, 1655, 1612. 1H NMR (DMSO‑d) δ (ppm): 3.57 (s, 3H, OCH3), 3.71 (d, J = 16.9 Hz, 1H upfield H of CH2CO), 3.86 (s, 3H, NCH3), 4.33 (d, J = 16.9 Hz, 1H, downfield H of CH2CO), 6.27 (s, 1H, OH), 6.73 (s, 2H, arom. H), 6.94 (s, 1H, arom. H), 7.35 (t, J = 7.0 Hz, 1H, arom. H), 7.43 (t, J = 7.2 Hz, 1H, arom. H), 7.63 (d, J = 8.0 Hz, 1H, arom. H), 7.84 (d, J = 8.0 Hz, 1H, arom. H), 10.17 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 31.9 (NCH3), 46.8 (CH2CO), 55.3 (OCH3), 73.6 (indolyl C-3) 109.9, 111.0, 111.5, 113.7, 121.2, 123.6, 125.7, 132.4, 135.8, 136.7, 140.8, 145.7, 154.6 (arom. C), 178.0 [indolyl CO (C-2)], 191.3 (ketonic CO). Anal. Calcd. for C19H17N3O4 (351.36): C, 64.95; H, 4.88; N, 11.96. Found: C, 65.13; H, 5.01; N, 12.07.

3-[2-(1-Ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]-3-hydroxy-5-methoxyindolin-2-one (12f)

It was obtained from the reaction of 4c and 11b as colorless solid with mp 179–181 °C and yield 89% (1.62 g). IR: ν max/cm−1 3422, 3167, 1709, 1682, 1639. 1H NMR (DMSO‑d) δ (ppm): 1.11 (t, J = 6.3 Hz, 3H, CH3), 3.54 (s, 3H, OCH3), 3.67 (d, J = 16.3 Hz, 1H upfield H of CH2CO), 4.33–4.42 (m, 3H, NCHCH3 + downfield H of CH2CO), 6.29 (s, 1H, OH), 6.72 (s, 2H, arom. H), 6.91 (s, 1H, arom. H), 7.36 (t, J = 7.2 Hz, 1H, arom. H), 7.43 (t, J = 7.2 Hz, 1H, arom. H), 7.67 (d, J = 8.0 Hz, 1H, arom. H), 7.86 (d, J = 8.0 Hz, 1H, arom. H), 10.17 (s, 1H, NH). 13C NMR (DMSO‑d) δ (ppm): 15.1 (CH3), 39.7 (NCH2CH3), 46.7 (CH2CO), 55.3 (OCH3), 73.8 (indolyl C-3) 109.9, 111.0, 111.5, 113.9, 121.3, 123.6, 125.8, 132.3, 135.7, 141.0, 145.2, 154.6 (arom. C), 177.9 [indolyl CO (C-2)], 191.2 (ketonic CO). Anal. Calcd. for C20H19N3O4 (365.39): C, 65.74; H, 5.24; N, 11.50. Found: C, 65.81; H, 5.33; N, 11.68.

3-Hydroxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]-1-(piperidin-1-ylmethyl)indolin-2-one (12 g)

It was obtained from the reaction of 4d [97] and 11a as colorless solid with mp 147–149 °C and yield 75% (1.57 g). IR: ν max/cm−1 3321, 1701, 1686, 1616. 1H NMR (DMSO‑d) δ (ppm): 1.36 (br s, 2H, piperidinyl H2C-4), 1.47 (br s, 4H, piperidinyl H2C-3/5), 2.57 (br d, 4H, piperidinyl H2C-2/6), 3.79 (d, J = 17.1 Hz, 1H upfield H of CH2CO), 3.84 (s, 3H, NCH3), 4.37–4.40 (m, 3H, NCH2N + downfield H of CH2CO), 6.37 (s, 1H, OH), 6.92 (t, J = 6.9 Hz, 1H, arom. H), 7.11 (d, J = 7.4 Hz, 1H, arom. H), 7.24 (t, J = 7.3 Hz, 1H, arom. H), 7.35 (br s, 2H, arom. H), 7.42 (t, J = 7.3 Hz, 1H, arom. H), 7.62 (d, J = 7.9 Hz, 1H, arom. H), 7.83 (d, J = 7.8 Hz, 1H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 23.8 (piperidinyl C-4), 25.4 (piperidinyl C-3/5), 31.8 (NCH3), 47.0 (CH2CO), 51.3 (piperidinyl C-2/6), 62.1 (NCH2N), 72.9 (indolyl C-3), 109.9, 111.5, 121.2, 121.9, 123.4, 123.5, 125.7, 129.1, 130.4, 136.7, 140.8, 144.2, 145.5 (arom. C), 177.4 [indolyl CO (C-2)], 191.1 (ketonic CO). Anal. Calcd. for C24H26N4O3 (418.50): C, 68.88; H, 6.26; N, 13.39. Found: C, 69.01; H, 6.10; N, 13.58.

3-Hydroxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethyl]-1-(morpholinomethyl)indolin-2-one (12 h)

It was obtained from the reaction of 4e [97] and 11a as pale yellow solid with mp 168–170 °C and yield 77% (1.61 g). IR: ν max/cm−1 3283, 1717, 1686, 1612. 1H NMR (DMSO‑d) δ (ppm): 2.61 (br d, 4H, morpholinyl 2 NCH2), 3.57 (br s, 4H, morpholinyl 2 OCH2), 3.81 (d, J = 16.3 Hz, 1H upfield H of CH2CO), 3.83 (s, 3H, NCH3), 4.38–4.44 (m, 3H, NCH2N + downfield H of CH2CO), 6.40 (s, 1H, OH), 6.95 (t, J = 6.8 Hz, 1H, arom. H), 7.14 (d, J = 7.5 Hz, 1H, arom. H), 7.26 (t, J = 6.7 Hz, 1H, arom. H), 7.36 (br s, 2H, arom. H), 7.42 (t, J = 7.1 Hz, 1H, arom. H), 7.62 (d, J = 8.0 Hz, 1H, arom. H), 7.84 (d, J = 7.9 Hz, 1H, arom. H). 13C NMR (DMSO‑d) δ (ppm): 31.8 (NCH3), 46.9 (CH2CO), 50.6 (morpholinyl NCH2), 61.4 (NCH2N), 66.1 (morpholinyl OCH2), 72.9 (indolyl C-3) 109.8, 111.5, 121.2, 122.1, 123.4, 123.6, 125.7, 129.1, 130.4, 136.7, 140.8, 143.9, 145.5 (arom. C), 177.4 [indolyl CO (C-2)], 191.2 (ketonic CO). Anal. Calcd. for C23H24N4O4 (420.47): C, 65.70; H, 5.75; N, 13.33. Found: C, 65.51; H, 5.81; N, 13.47.

Acidic dehydration of 12a-h (general procedure)

Hydrochloric acid (25 ml, 25%) was added dropwise (10 min.) to a magnetically stirred solution of 12a-h (5 mmol) in absolute ethanol (12.5 ml) at room temperature (20–25 °C). The reaction mixture was kept stirring under the same conditions for 4 h and stored overnight at room temperature. The separated solid was collected, washed with water and crystallized from a suitable solvent affording the corresponding 13a-f.

(E)-3-[2-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-one (13a)

It was obtained from acidic dehydration of 12a, 12 g or 12 h as colorless microcrystals from N,N-dimethylformamide with mp 349–350 °C and yield 84, 73, 77% (1.27, 1.10, 1.16 g from reaction of 12a, 12 g and 12 h, respectively). IR: ν max/cm−1 3124, 1694, 1585. 1H NMR (CF3CO2D) δ (ppm): 4.26 (s, 3H, NCH3), 7.57–7.91 (m, 6H, arom. H), 8.21 (d, J = 8.4 Hz, 1H, arom. H), 8.66 (s, 1H, olefinic H), 8.83 (d, J = 8.5 Hz, 1H, arom. H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 35.3 (NCH3), 114.9, 116.8, 125.4, 128.4, 1629.0, 130.4, 131.2, 131.7, 132.4, 135.4, 136.0, 136.5, 141.1, 141.6, 146.0 (arom. C + olefinic C), 149.8 [indolyl CO (C-2)], 171.6 (ketonic CO). Anal. Calcd. for C18H13N3O2 (303.32): C, 71.28; H, 4.32; N, 13.85. Found: C, 71.49; H, 4.46; N, 14.01.

(E)-3-[2-(1-Ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-one (13b)

It was obtained from acidic dehydration of 12b as colorless microcrystals from n-butanol with mp 301–303 °C and yield 75% (1.19 g). IR: ν max/cm−1 3129, 1697, 1589. 1H NMR (CF3CO2D) δ (ppm): 1.75 (t, J = 7.2 Hz, 3H, NCH2CH3), 4.99 (q, J = 7.2 Hz, 2H, NCH2), 7.70–7.76 (m, 2H, arom. H), 7.84–7.85 (m, 2H, arom. H), 7.94 (t, J = 7.7 Hz, 1H, arom. H), 8.03 (t, J = 7.6 Hz, 1H, arom. H), 8.35 (d, J = 8.5 Hz, 1H, arom. H), 8.81 (s, 1H, olefinic H), 8.99 (d, J = 8.7 Hz, 1H, arom. H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 15.5 (CH3), 45.0 (NCH2), 114.7, 116.6, 124.7, 127.9, 128.4, 130.7, 131.17, 131.22, 132.4, 134.8, 135.0, 135.6, 142.0, 145.9 (arom. C + olefinic C), 150.5 [indolyl CO (C-2)], 171.9 (ketonic CO). Anal. Calcd. for C19H15N3O2 (317.35): C, 71.91; H, 4.76; N, 13.24. Found: C, 71.79; H, 4.68; N, 13.05.

(E)-5-Chloro-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-one (13c)

It was obtained from acidic dehydration of 12c as colorless microcrystals from N,N-dimethylformamide with mp 354–356 °C and yield 98% (1.65 g). IR: ν max/cm−1 3117, 1694, 1585. 1H NMR (CF3CO2D) δ (ppm): 4.42 (s, 3H, NCH3), 7.63–7.81 (m, 5H, arom. H), 8.17 (d, J = 9.0 Hz, 1H, arom. H), 8.77 (s, 1H, olefinic H), 8.91 (br s, 1H, arom. H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 35.3 (NCH3), 114.7, 116.6, 125.8, 127.0, 128.8, 130.8, 131.4, 132.2, 133.7, 136.09, 136.14, 137.6, 142.4, 143.0, 147.1 (arom. C + olefinic C), 149.9 [indolyl CO (C-2)], 171.8 (ketonic CO). Anal. Calcd. for C18H12ClN3O2 (337.76): C, 64.01; H, 3.58; N, 12.44. Found: C, 63.85; H, 3.39; N, 12.30.

(E)-5-Chloro-3-[2-(1-ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-one (13d)

It was obtained from acidic dehydration of 12d as colorless microcrystals from N,N-dimethylformamide with mp 325–327 °C and yield 93% (1.63 g). IR: ν max/cm−1 3129, 1694, 1585. 1H NMR (CF3CO2D) δ (ppm): 1.77 (t, J = 7.2 Hz, 3H, NCH2CH3), 5.04 (q, J = 7.1 Hz, 2H, NCH2), 7.69–7.75 (m, 2H, arom. H), 7.83–7.91 (m, 3H, arom. H), 8.24 (d, J = 9.1 Hz, 1H, arom. H), 8.85 (s, 1H, olefinic H), 9.01 (d, J = 1.8 Hz, 1H, arom. H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 15.5 (CH3), 45.0 (NCH2), 114.6, 116.5, 125.4, 126.9, 128.6, 130.6, 131.1, 132.3, 133.8, 134.9, 135.9, 137.3, 142.2, 143.0, 146.4 (arom. C + olefinic C), 150.0 [indolyl CO (C-2)], 171.8 (ketonic CO). Anal. Calcd. for C19H14ClN3O2 (351.79): C, 64.87; H, 4.01; N, 11.94. Found: C, 64.76; H, 4.09; N, 11.77.

(E)-5-Methoxy-3-[2-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]indolin-2-one (13e)

It was obtained from acidic dehydration of 12e as pale yellow microcrystals from N,N-dimethylformamide with mp 328–330 °C and yield 91% (1.52 g). IR: ν max/cm−1 3121, 1694, 1620. 1H NMR (CF3CO2D) δ (ppm): 3.94 (s, 3H, OCH3), 4.26 (s, 3H, NCH3), 7.63–7.74 (m, 5H, arom. H), 8.19 (d, J = 9.4 Hz, 1H, arom. H), 8.37 (br s, 1H, arom. H), 8.78 (s, 1H, olefinic H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 35.1 (NCH3), 57.9 (OCH3), 106.0, 114.8, 116.7, 126.8, 130.3, 131.2, 131.4, 131.7, 132.2, 132.4, 135.8, 136.3, 138.9, 145.0, 145.2 (arom. C + olefinic C), 166.3 [indolyl CO (C-2)], 171.1 (ketonic CO). Anal. Calcd. for C19H15N3O3 (333.35): C, 68.46; H, 4.54; N, 12.61. Found: C, 68.61; H, 4.68; N, 12.53.

(E)-3-[2-(1-Ethyl-1H-benzo[d]imidazol-2-yl)-2-oxoethylidene]-5-methoxyindolin-2-one (13f)

It was obtained from acidic dehydration of 12f as pale yellow microcrystals from N,N-dimethylformamide with mp 317–319 °C and yield 95% (1.65 g). IR: ν max/cm−1 3121, 1694, 1620. 1H NMR (CF3CO2D) δ (ppm): 1.63 (t, J = 7.2 Hz, 3H, NCH2CH3), 3.96 (s, 3H, OCH3), 4.82 (q, J = 7.1 Hz, 2H, NCH2), 7.61–7.66 (m, 3H, arom. H), 7.75 (t, J = 5.9 Hz, 2H, arom. H), 8.18 (d, J = 9.4 Hz, 1H, arom. H), 8.38 (d, J = 2.4 Hz, 1H, arom. H), 8.77 (s, 1H, olefinic H), 11.50 (s, 1H, NH). 13C NMR (CF3CO2D) δ (ppm): 15.6 (CH3), 45.1 (NCH2), 57.8 (OCH3), 105.9, 114.8, 116.8, 126.2, 130.3, 130.9, 131.4, 131.7, 132.6, 134.8, 137.4, 137.8, 145.3, 146.3 (arom. C + olefinic C), 165.9 [indolyl CO (C-2)], 171.6 (ketonic CO). Anal. Calcd. for C20H17N3O3 (347.37): C, 69.15; H, 4.93; N, 12.10. Found: C, 68.96; H, 4.75; N, 11.99.

Mentioned in details in the supplementary file.

Mentioned in details in the supplementary file.

Docking studies

Mentioned in details in the supplementary file.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.